The following video is part of our "Motley Fool Conversations" series, in which analyst Jim Mueller and analyst Jason Moser discuss topics around the investing world.

Dendreon (Nasdaq: DNDN) has had a volatile history as a stock as it developed and then brought to market its prostate cancer drug, Provenge. Today, Motley Fool Stock Advisor analysts Jim Mueller and Jason Moser discuss why today might finally be the time to invest in this biotech company.